Market capitalization | $215.11m |
Enterprise Value | $-9.58m |
P/B ratio (TTM) P/B ratio | 1.21 |
Cash position | $196.33m |
P/E forward | 0.14 |
P/S forward | 2,151.10 |
EV/Sales forward | negative |
Short interest | 5.71% |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
2 Analysts have issued a Inhibrx Inc forecast:
2 Analysts have issued a Inhibrx Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.76 -0.76 |
300%
300%
|
|
EBITDA | -46 -46 |
1%
1%
|
EBIT (Operating Income) EBIT | -47 -47 |
2%
2%
|
Net Profit | -44 -44 |
15%
15%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Inhibrx, Inc. engages in researching and developing biotechnology. It is a clinical stage company, which focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.
Head office | United States |
CEO | Mark Lappe |
Founded | 2010 |
Website | www.inhibrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.